Scarica l'app Stockscreener
19.00
0.21%
-0.04
Precedente Chiudi:
$19.04
Aprire:
$19.6
Volume 24 ore:
3.99M
Relative Volume:
2.34
Capitalizzazione di mercato:
$1.68B
Reddito:
$217.42M
Utile/perdita netta:
$-243.25M
Rapporto P/E:
-6.7974
EPS:
-2.7952
Flusso di cassa netto:
$-278.35M
1 W Prestazione:
+6.09%
1M Prestazione:
-2.11%
6M Prestazione:
-6.08%
1 anno Prestazione:
+96.08%
Intervallo 1D:
$18.93
$20.37
Intervallo di 1 settimana:
$17.73
$20.37
Portata 52W:
$8.585
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Nome
Syndax Pharmaceuticals Inc
Settore
Industria
Telefono
781-419-1400
Indirizzo
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
19.00 | 1.68B | 217.42M | -243.25M | -278.35M | -2.7952 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-16 | Ripresa | H.C. Wainwright | Buy |
| 2025-09-10 | Ripresa | Stifel | Buy |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-08-05 | Reiterato | BTIG Research | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-06-28 | Iniziato | Jefferies | Buy |
| 2024-01-31 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-10-25 | Iniziato | BofA Securities | Buy |
| 2023-10-11 | Iniziato | Goldman | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-11 | Iniziato | Guggenheim | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2023-01-03 | Iniziato | JP Morgan | Overweight |
| 2022-07-28 | Ripresa | B. Riley Securities | Buy |
| 2022-04-11 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-15 | Iniziato | Goldman | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-25 | Iniziato | Citigroup | Buy |
| 2021-02-18 | Iniziato | B. Riley Securities | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Downgrade | Citigroup | Buy → Neutral |
| 2020-05-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-01-04 | Iniziato | Robert W. Baird | Outperform |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Iniziato | FBR & Co. | Outperform |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2016-10-07 | Iniziato | Guggenheim | Buy |
| 2016-03-28 | Iniziato | Citigroup | Buy |
| 2016-03-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-03-28 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie
Ishara Investments LP Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Catalio Capital Management LP - MarketBeat
Eversept Partners LP Decreases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Syndax Pharmaceuticals Inc - TradingKey
Apis Capital Advisors LLC Acquires 86,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Syndax Pharmaceuticals stock gains test resistance near $19.68 after EHA congress participation - Traders Union
(SNDX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Syndax Pharmaceuticals Inc (SNDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Syndax Pharmaceuticals Inc (SNDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Syndax Pharmaceuticals Inc (SNDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Syndax Pharmaceuticals Inc (SNDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Syndax Pharmaceuticals Inc (SNDX) Institutional Confidence - TradingKey
Syndax Pharmaceuticals Inc (SNDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Syndax Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
Syndax Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Eventide Asset Management LLC Has $26.01 Million Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (SNDX) Stock Valuation After Positive SAVE Trial Data In High-Risk Leukemia - Sahm
Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial DataWhat's Changed - Yahoo Finance
Voss Capital LP Buys Shares of 125,000 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Rhenman & Partners Asset Management AB Sells 87,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
SNDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Syndax (SNDX) CMO sells 65,515 shares, retains 60,885 and large options - Stock Titan
SNDX (NASDAQ) Rule 144 notice: Director-linked sale of 31,235 shares - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
SNDX Stock Price, Quote & Chart - ChartMill
[144] Syndax Pharmaceuticals Inc SEC Filing - Stock Titan
Syndax showcases revuforj (revumenib) data at EHA 2026 - grafa.com
Syndax (SNDX) Reveals Encouraging Results from SAVE Trial for AM - GuruFocus
Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced (NASDAQ:SNDX) - Seeking Alpha
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026 - The Manila Times
Leukemia drug revumenib shows up to 97% remission in EHA 2026 data - Stock Titan
Syndax Pharmaceuticals Announces Publication of Save Data on Revuforj in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML - marketscreener.com
SNDX6417984 Bond Coupon Analysis — Rate & Payments - TradingView
Syndax Pharmaceuticals (NASDAQ: SNDX) issues $250M 2.25% convertible notes due 2031 - Stock Titan
Syndax (NASDAQ: SNDX) investors back 2026 equity plan and new ESPP - Stock Titan
Syndax Pharmaceuticals, Inc. Bonds — Corporate Bond Rates - TradingView
Syndax Pharmaceuticals Inc Bonds — Corporate Bond Rates - TradingView
Syndax Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:SNDX) - MarketBeat
SNDX6417984 Bond Analysis — Key Metrics - TradingView
Transcript : Syndax Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 02 - marketscreener.com
SNDX: Revuforj's clinical success and expanding pipeline drive growth, with new capital fueling future innovation - TradingView
Syndax Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
SNDX6417984 Bond Price and Chart — FINRA:SNDX6417984 - TradingView
Price-Driven Insight from (SNDX) for Rule-Based Strategy - Stock Traders Daily
A Look At Syndax Pharmaceuticals (SNDX) Valuation After Recent Share Price Weakness - Sahm
Syndax Pharmaceuticals prices $250M senior convertible notes - MSN
Syndax Pharmaceuticals prices $250 million convertible notes By Investing.com - Investing.com Australia
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax (SNDX) Launches $250M Convertible Senior Note Offering - GuruFocus
Syndax Pharmaceuticals Inc Azioni (SNDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):